Organogenesis Holdings (ORGO) Change in Account Payables (2018 - 2026)
Organogenesis Holdings (ORGO) posted quarterly Change in Account Payables of -$2.0 million for Q1 2026, up 19.75% year-over-year from -$1.7 million in Q1 2025, and down 71.05% quarter-over-quarter from -$1.2 million in Q4 2025.
Organogenesis Holdings (ORGO) Change in Account Payables (2018 - 2026) Analysis & Trends
Organogenesis Holdings' Change in Account Payables history runs 9 years deep, the most recent figure standing at -$2.0 million for Q1 2026.
- In Q1 2026, Change in Account Payables rose 19.75% year-over-year to -$2.0 million; the TTM figure through Mar 2026 stood at -$35000.0 (up 92.66% YoY), while the FY2025 annual figure was -$528000.0, up 77.74% from the prior year.
- Change in Account Payables for Q1 2026 stood at -$2.0 million, down from -$1.2 million in the prior quarter.
- The five-year high for Change in Account Payables was $4.1 million in Q2 2025, with the low at -$4.4 million in Q1 2024.
- The 5-year median for Change in Account Payables is -$1.2 million (2025), against an average of -$103000.0.
- The sharpest annual moves came in 2022 and 2024: Change in Account Payables soared 442.54% in 2022, then tumbled 2975.4% in 2024.
- Organogenesis Holdings' Change in Account Payables stood at -$2.0 million in 2022, then surged by 277.56% to $3.6 million in 2023, then grew by 2.73% to $3.6 million in 2024, then slumped by 132.08% to -$1.2 million in 2025, then slumped by 71.05% to -$2.0 million in 2026.
- Business Quant data shows ORGO's Change in Account Payables at -$2.0 million in Q1 2026, -$1.2 million in Q4 2025, and -$994000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Account Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.89 Bn | 42.93 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 42.98 Bn | 39.33 Bn | 2.15 Bn | - |
| 3 | Zoetis | 31.54 Bn | 29.86 Bn | 1.05 Bn | -53.00 Mn |
| 4 | Takeda Pharmaceutical | 28.61 Bn | 22.81 Bn | 5.10 Bn | -143.74 Mn |
| 5 | United Therapeutics | 22.15 Bn | 19.48 Bn | 683.80 Mn | - |
| 6 | Viatris | 18.75 Bn | 17.86 Bn | 1.46 Bn | -21.20 Mn |
| 7 | Neurocrine Biosciences | 15.56 Bn | 15.17 Bn | 935.80 Mn | - |
| 8 | Elanco Animal Health | 11.74 Bn | 11.21 Bn | 798.00 Mn | - |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.95 Bn | - | - |
| 10 | Organogenesis Holdings | 241.78 Mn | 194.94 Mn | 20.08 Mn | 605,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 605,000.00 |
| Jun 30, 2026 | 605,000.00 |
| Mar 31, 2026 | -2.00 Mn |
| Mar 31, 2026 | -2.00 Mn |
| Dec 31, 2025 | -1.17 Mn |
| Dec 31, 2025 | -1.17 Mn |
| Sep 30, 2025 | -994,000.00 |
| Sep 30, 2025 | -994,000.00 |
| Jun 30, 2025 | 4.13 Mn |
| Jun 30, 2025 | 4.13 Mn |
| Mar 31, 2025 | -2.50 Mn |
| Mar 31, 2025 | -2.50 Mn |
| Dec 31, 2024 | 3.65 Mn |
| Dec 31, 2024 | 3.65 Mn |
| Sep 30, 2024 | -3.88 Mn |
| Sep 30, 2024 | -3.88 Mn |
| Jun 30, 2024 | 2.24 Mn |
| Jun 30, 2024 | 2.24 Mn |
| Mar 31, 2024 | -4.39 Mn |
| Mar 31, 2024 | -4.39 Mn |